Publication

Replacing procarbazine with dacarbazine in escalated beacopp dramatically reduces the post treatment haematopoietic stem and progenitor cell mutational burden in hodgkin lymphoma patients with no apparent loss of clinical efficacy

Santarsieri, A.
; 
Mitchell, E.
; 
Sturgess, K.
; 
Brice, P.
; 
Menne, T. F.
; 
Osborne, W.
; 
Creasey, T.
; 
Ardeshna, K. M.
; 
Behan, S.
; 
Bhuller, K.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Santarsieri, A.
Mitchell, E.
Sturgess, K.
Brice, P.
Menne, T. F.
Osborne, W.
Creasey, T.
Ardeshna, K. M.
Behan, S.
Bhuller, K.
Booth, S.
Chavda, N. D.
Collins, G. P.
Culligan, D. J.
Cwynarski, K.
Davies, A.
Downing, A.
Dutton, D.
Furtado, M.
Gallop-Evans, E.
Hodson, A.
Hopkins, D.
Hsu, H.
Iyengar, S.
Jones, S. G.
Linton, Kim M
Lomas, O. C.
Martinez-Calle, N.
Mathur, A.
McKay, P.
Nagumantry, S. K.
O'Mahony, D.
Phillips, Elizabeth H
Phillips, N.
Rudge, J. F.
Shah, N. K.
Stafford, G.
Sternberg, A.
Trickey, R.
Uttenthal, B. J.
Wetherall, N.
McMillan, A. K.
Stratton, M.
Laurenti, E.
Campbell, P. J.
Follows, G. A.
Affiliation
Cambridge University Hospitals NHS Foundation Trust, Cambridge
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Santarsieri A, Mitchell E, Sturgess K, Brice P, Menne TF, Osborne W, et al. Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy. Blood. 2022 Nov;140:1761-4. PubMed PMID: WOS:000893223201318.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626115
Embedded videos